When dosed as bare compounds, MABs and non MAB proteins will not be able to
survive passage of the stomach and hence will not be available for uptake from
the intestinal tract into circulation.
BiOraliX protein formulation technology enables intestinal uptake of MAb's and
non-MAb proteins via oral administration. This nanoparticle formation technology
provides an excellent foundation for protein-optimized formulation composition to
guarantee for the best absorption profile (rate and efficiency of absorption) after
passing the stomach. Once transported from the duodenum to circulation, the
protein is entirely and fully functionally available for its pharmacological activity.
In 3 consecutive preclinical studies with increasing complexity BiOraliX has
demonstrated that the bioavailability of the oral delivery technology, with
omalizumab as test compound, was more than 2 times higher than
Feel free to contact us to learn more.